Cargando…
The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis
BACKGROUND: Previous studies have demonstrated the benefits of thymosin alpha-1 (Tα1) in anti-virus, immunological enhancement and anti-inflammation. However, it is controversial about the efficacy and safety of entecavir (ETV) plus Tα1 combination therapy versus ETV monotherapy in cirrhotic patient...
Autores principales: | Peng, Dan, Xing, Hai-Yan, Li, Chen, Wang, Xian-Feng, Hou, Min, Li, Bin, Chen, Jian-Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574490/ https://www.ncbi.nlm.nih.gov/pubmed/33076834 http://dx.doi.org/10.1186/s12876-020-01477-8 |
Ejemplares similares
-
Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015) -
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020) -
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015) -
Antiviral Efficacy of Entecavir versus Entecavir plus Adefovir for Hepatitis B Virus rtA181V/T Mutants Alone
por: Oh, Myung Jin, et al.
Publicado: (2016) -
Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice
por: Qi, Ruoyao, et al.
Publicado: (2023)